Spots Global Cancer Trial Database for relapse
Every month we try and update this database with for relapse cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse | NCT00083681 | Multiple Myelom... | Thalidomide Dexamethasone Cytoxan Etoposide Cisplatin G-CSF | 18 Years - | University of Arkansas | |
| The circTeloDIAG: Liquid Biopsy for Glioma Tumor | NCT04931732 | Glioma | ctDNA analysis | 18 Years - 90 Years | Hospices Civils de Lyon | |
| Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma | NCT00799513 | Diffuse Large B... | Lenalidomide | 18 Years - | IRCCS San Raffaele | |
| MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT | NCT02673008 | Minimal Residua... Donor Lymphocyt... Hematopoietic S... Relapse | donor lymphocyt... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | NCT02298348 | Neuroblastoma | Sorafenib Cyclophosphamid... Topotecan | - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) | NCT00368082 | Lymphoma Hodgkin's Disea... Relapse Lymphoma, Non-H... | TGFbeta resista... | - | Baylor College of Medicine | |
| Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer | NCT00116610 | Small Cell Lung... | picoplatin | 18 Years - | Poniard Pharmaceuticals | |
| Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma | NCT05135858 | Primary Central... | Glucarpidase Methotrexate (M... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies | NCT01385072 | Relapsed and Re... | Double matched ... | 18 Years - | Rabin Medical Center | |
| Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells | NCT03236129 | Hematological M... Regulatory T Ce... Relapse | T-reg depleted ... Standard DLI | - | Assistance Publique - Hôpitaux de Paris | |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies | NCT03771222 | Donor Lymphocyt... Peripheral Bloo... Relapse Graft-versus-ho... Decitabine | Prophylactic DL... | 14 Years - 65 Years | Chinese PLA General Hospital | |
| Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma | NCT01606605 | Diffuse Large B... | 15 Years - 90 Years | Samsung Medical Center | ||
| Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk | NCT03000335 | B-cell Acute Ly... | 2 Years - 19 Years | Curewize Health Ltd. | ||
| Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP | NCT02983097 | Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Burkitt Lymphom... Aggressive Marg... | Rituximab Cisplatin Carboplatin Dexamethasone Cytarabine Lenalidomide PegFilgrastim peripheral stem... | 18 Years - 70 Years | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients | NCT00631059 | Leukemia | Hem(A)+ Technol... | 18 Years - | University of California, Irvine | |
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | NCT05137886 | Hodgkin Lymphom... Relapse Refractory Hodg... | PD-1 inhibitor | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia | NCT03765541 | Relapsed or Ref... | Dexamethasone Amsacrine Cytarabine Azacitidine | 18 Years - | University Hospital, Toulouse | |
| Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | NCT02245867 | Amyloidosis | Chimeric Fibril... | 21 Years - | Columbia University | |
| Gut Mucosal Microbiota is Associated With Colorectal Cancer Relapse | NCT03385213 | Gut Microbiota Colorectal Canc... | 35 Years - 80 Years | First Affiliated Hospital of Harbin Medical University | ||
| A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03372057 | Peripheral T-ce... | Duvelisib Duvelisib Duvelisib | 18 Years - | SecuraBio | |
| CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | NCT03029338 | Lymphomas Non-H... Relapse | CD19 CAR T cell... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS | NCT02204020 | Acute Myeloid L... Myelodysplastic... | 5-azacytidine (... | 18 Years - | University of Pittsburgh | |
| Epigenetic Reprogramming in Relapse/Refractory AML | NCT03263936 | Acute Myelogeno... | Decitabine Vorinostat Filgrastim (G-C... Fludarabine Cytarabine | 1 Year - 25 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma | NCT01606605 | Diffuse Large B... | 15 Years - 90 Years | Samsung Medical Center | ||
| Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse | NCT01794572 | Multiple Myelom... | Melphalan Autologous Hema... | 18 Years - 65 Years | Institut Cancerologie de l'Ouest | |
| Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation | NCT02631499 | Carcinoma, Hepa... Neoplastic Cell... | TACE Epirubicin lipiodol | 18 Years - 75 Years | Fudan University | |
| CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | NCT03029338 | Lymphomas Non-H... Relapse | CD19 CAR T cell... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | NCT01481701 | Ovarian Carcino... Relapse | Oxaliplatin oxaliplatin | 18 Years - | Jules Bordet Institute | |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | NCT06090864 | Hodgkin Lymphom... Relapse Refractory | Chemotherapy Cell infusion | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse | NCT00335348 | Multiple Myelom... | Bortezomib Dexamethasone | 18 Years - 80 Years | Peter MacCallum Cancer Centre, Australia | |
| A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | NCT05537740 | Advanced Solid ... | BAY3375968 Pembrolizumab | 18 Years - | Bayer | |
| A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | NCT01470131 | Multiple Myelom... | Masitinib Placebo Bortezomib Dexamethasone | 18 Years - | AB Science | |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | NCT06347068 | Breast Cancer Relapse Resistant Cance... Triple Negative... | iC9-CAR.B7-H3 T... cyclophosphamid... fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy | NCT00230217 | Tumors Hyperuricemia Tumor Lysis Syn... | Rasburicase (SR... | - | Sanofi | |
| EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT01186328 | Lymphoblastic L... Lymphoblastic L... Leukemia, Lymph... Leukemia, Lymph... | EZN-3042 Cytarabine Doxorubicin Prednisone Vincristine PEG-asparaginas... Methotrexate Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT01310101 | Chronic Lymphoc... | ofatumumab plus... | 18 Years - | Brno University Hospital | |
| ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia | NCT00114348 | Lymphoblastic L... Lymphoma, Non-H... | R-Blocks Protocol II-Ida | - 18 Years | Charite University, Berlin, Germany | |
| Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia | NCT00723346 | Acute Lymphobla... | GRASPA GRASPA GRASPA native L aspara... | 1 Year - 55 Years | ERYtech Pharma | |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies | NCT02145403 | Hematologic Mal... Relapse Graft-Versus-Ho... | Carfilzomib Tacrolimus | 18 Years - 70 Years | University of Michigan Rogel Cancer Center | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT01310101 | Chronic Lymphoc... | ofatumumab plus... | 18 Years - | Brno University Hospital | |
| Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML | NCT00363974 | Leukemia, Myelo... | XIAP antisense | 18 Years - | Aegera Therapeutics | |
| Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer | NCT02948309 | Pancreatic Canc... | Mistletoe extra... Placebo | 18 Years - | Karolinska University Hospital | |
| Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer | NCT00888810 | Cancer Ovarian Relapse Chemotherapy | TOPOTECAN LAPATINIB | 18 Years - | Centre Francois Baclesse | |
| Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia | NCT00167167 | Leukemia, Myelo... AML MDS Leukemia, Lymph... | Donor Lymphocyt... | 1 Year - 60 Years | Masonic Cancer Center, University of Minnesota | |
| CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | NCT03029338 | Lymphomas Non-H... Relapse | CD19 CAR T cell... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence After prostatectomy-a Prospective Observational Study | NCT05455736 | Prostate Cancer Relapse | Stereotactic sa... | 18 Years - | Azienda Ospedaliero-Universitaria Careggi | |
| Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL | NCT01612988 | B-cell Chronic ... | BOMP | 18 Years - 80 Years | French Innovative Leukemia Organisation | |
| A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression | NCT00482261 | Multiple Myelom... | Lenalidomide dexamethasone aspirin | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | NCT00822094 | Acute Myeloid L... | CPX-351 Intensive Salva... | 18 Years - 65 Years | Jazz Pharmaceuticals | |
| A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | NCT03697629 | Multiple Myelom... | Daratumumab | 18 Years - | Canadian Myeloma Research Group | |
| Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma | NCT02515084 | Thyroid Cancer Relapse | PET MRI imaging | 18 Years - | Centre Henri Becquerel | |
| Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) | NCT02163720 | Ovarian Cancer | Yondelis®-Caely... | 18 Years - | ARCAGY/ GINECO GROUP | |
| A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03372057 | Peripheral T-ce... | Duvelisib Duvelisib Duvelisib | 18 Years - | SecuraBio | |
| Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia | NCT04723901 | Dual-target CAR... B ALL Relapse Refractory B Ac... | Dual target CAR... | 14 Years - 75 Years | Shenzhen University General Hospital | |
| MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT | NCT02673008 | Minimal Residua... Donor Lymphocyt... Hematopoietic S... Relapse | donor lymphocyt... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia | NCT03765541 | Relapsed or Ref... | Dexamethasone Amsacrine Cytarabine Azacitidine | 18 Years - | University Hospital, Toulouse | |
| Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | NCT01889420 | Multiple Myelom... | Combination the... | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | NCT01321346 | Lymphoblastic L... Myelogenous Leu... Hodgkin's Disea... Non-Hodgkin's L... | Panobinostat Cytarabine Panobinostat | 8 Years - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas | NCT01788189 | B-cell Lymphoma | Lenalidomide | 18 Years - | University Hospital, Essen | |
| Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma | NCT02515084 | Thyroid Cancer Relapse | PET MRI imaging | 18 Years - | Centre Henri Becquerel | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | NCT00984165 | Hodgkin's Lymph... Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | Single fraction... Donor Lymphocyt... Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD | NCT05137860 | Acute Lymphobla... Chemotherapeuti... Minimal Residua... | Bortezomib | 18 Years - 50 Years | Hospital General de Mexico | |
| Understanding Communication in Healthcare to Achieve Trust (U-CHAT) | NCT02846038 | Brain Tumors Solid Tumor | - | St. Jude Children's Research Hospital | ||
| Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents | NCT01517776 | Gliomas | Cilengitide Temozolomide | 3 Years - 17 Years | Martin-Luther-Universität Halle-Wittenberg | |
| Treatment of Acute Leukemia Relapse After Allotransplantation | NCT01369368 | Acute Myeloid L... | Combined use of... | 18 Years - 90 Years | University of Bergen | |
| UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | NCT02140840 | Multiple Myelom... | Trametinib | 18 Years - | University of Arkansas | |
| Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia | NCT04674345 | Acute Leukemia Relapse Hematopoietic S... | Sorafenib | 18 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | NCT02245867 | Amyloidosis | Chimeric Fibril... | 21 Years - | Columbia University | |
| Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation | NCT03121079 | Interferon-A-2B Relapse Prevention Hematopietic St... | Interferon-alph... | 18 Years - 60 Years | Peking University People's Hospital | |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies | NCT03771222 | Donor Lymphocyt... Peripheral Bloo... Relapse Graft-versus-ho... Decitabine | Prophylactic DL... | 14 Years - 65 Years | Chinese PLA General Hospital | |
| DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse | NCT00083681 | Multiple Myelom... | Thalidomide Dexamethasone Cytoxan Etoposide Cisplatin G-CSF | 18 Years - | University of Arkansas | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| Smoking Relapse-Prevention Intervention for Cancer Patients | NCT01630161 | Smoking Cessati... | Usual Care Smoking Relapse... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | NCT00306813 | Relapse Refractory Mult... | Revlimid | 18 Years - | University of Wuerzburg | |
| Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation | NCT05250362 | Hematologic Mal... | Allogeneic Hema... | 18 Years - 60 Years | Sichuan University | |
| A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia | NCT00233909 | Leukemia, Myelo... | Zosuquidar gemtuzumab ozog... | 18 Years - | Kanisa Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
